# A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

> **NCT07472491** · PHASE2,PHASE3 · RECRUITING · sponsor: **GE Healthcare** · enrollment: 640 (estimated)

## Conditions studied

- Known or Highly Suspected Central Nervous System (CNS) Lesion
- Known or Highly Suspected Body (Excluding CNS) Lesion

## Interventions

- **DRUG:** Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL
- **DIAGNOSTIC_TEST:** MRI Scan
- **DRUG:** Gadobutrol

## Key facts

- **NCT ID:** NCT07472491
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 640 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07472491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07472491, "A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07472491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*